Hess G, Huttmann A, Witzens-Harig M, Dreyling MH, et al. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. Br J Haematol 2022 Apr 1. doi: 10.1111/bjh.18161.
PMID: 35362552